Posts filed under ‘Infecciones de transmision sexual’

Genital tract infection of women in Southern Orissa with special reference to pelvic inflammatory disease.

Indian J Sex Transm Dis. 2013 Jan;34(1):64-6.

Mohapatra S, Panda P, Parida B.

Source

Department of Microbiology, VMMC and Safdarjung Hospital, New Delhi, India.

FULL TEXT

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3730485/?report=classic

September 23, 2013 at 3:30 pm

Microbial and vaginal determinants influencing Mycoplasma hominis and Ureaplasma urealyticum genital colonization in a population of female patients.

Infez Med. 2013 Sep 1;21(3):201-6.

Leli C, Meucci M, Vento S, D’Alo F, Farinelli S, Perito S, Bistoni F, Mencacci A.

Source

Microbiology Section, Department of Experimental Medicine and Biochemical Sciences, University of Perugia, Perugia, Italy.

Abstract

Mycoplasma hominis and Ureaplasma urealyticum are associated with chorioamnionitis, preterm delivery and pelvic inflammatory disease. The aim of this study was to evaluate the possible risk factors of co-colonization by M. hominis in patients already colonized by U. urealyticum and compare demographic parameters, vaginal pH and microbiota of women colonized by U. urealyticum or M. hominis. A total of 452 patients positive for U. urealyticum or M. hominis were analysed, 421 (93.1%) of whom were positive for U. urealyticum and 31 (6.9%) for M. hominis. Patients positive for M. hominis compared to patients positive for U. urealyticum were more frequently colonized by Gardnerella vaginalis (71% vs 18.5%; p 0.0001), less frequently by lactobacilli (16.1% vs 61.5%; p 0.0001), and more frequently had a pH value higher than 4.5 (96.8% vs 57%; p 0.0001), all conditions associated to bacterial vaginosis (BV). Logistic regression analysis showed that only G. vaginalis colonization and pH higher than 4.5 were independently related to M. hominis colonization (respectively p 0.0001 and p 0.016). Thus, in women colonized by U. urealyticum, BV is an independent risk factor for M. hominis co-colonization.

abstract

http://www.infezmed.it/VisualizzaUnArticolo.aspx?Anno=2013&numero=3&ArticoloDaVisualizzare=Vol_21_3_2013_4

CLIC EN DOWNLOAD

September 23, 2013 at 3:28 pm

ICSI for treatment of human immunodeficiency virus and hepatitis C virus-serodiscordant couples with infected male partner.

Hum Reprod. 2005 Aug;20(8):2242-6.

Mencaglia L, Falcone P, Lentini GM, Consigli S, Pisoni M, Lofiego V, Guidetti R, Piomboni P, De Leo V.

Source

Centro di Chirurgia Ambulatoriale SrL, Via Toselle 178, 50144, Florence, Italy.

Abstract

BACKGROUND:

Assisted reproductive technology with semen washing can offer a significant reduction in risk of sexual and vertical transmission of human immunodeficiency virus (HIV) and hepatitis C virus (HCV) in serodiscordant couples with infected male partner.

METHODS:

Among couples coming to our centre for reproductive problems from January 2001 to December 2003, we selected 43 couples with seropositive male and seronegative female: 25 couples with HIV-seropositive males, 10 couples with HIV/hepatitis C virus (HCV)-seropositive males and eight couples with HCV-seropositive males. Sperm samples were washed and used for ICSI.

RESULTS:

Seventy-eight cycles of ICSI were performed. The mean fertilization rate was 70.34 +/- 20.14% (mean +/- SD). A mean number of 3.55 +/- 1.11 (range: 1-5) embryos of good quality was transferred for each patient. We obtained 22 pregnancies (21 singletons and one twin), with a pregnancy rate per transfer of 28.2% and an implantation rate per transfer of 15.2%. The cumulative pregnancy rate was 51.2%. At follow-up, no seroconversion was detected in any patient.

CONCLUSIONS:

Our data suggest that sperm wash and ICSI could be useful for reducing the risk of HIV and/or HCV transmission in serodiscordant couples with infected male wishing to have a child, irrespective of their fertility status.

PDF

http://humrep.oxfordjournals.org/content/20/8/2242.full.pdf+html

August 7, 2013 at 2:33 pm

Interventions to prevent sexually transmitted infections, including HIV infection.

Clin Infect Dis. 2011 Dec;53 Suppl 3:S64-78.

Marrazzo JM, Cates W.

Source

Department of Medicine, Division of Allergy and Infectious Diseases, University of Seattle, WA 98104, USA. jmm2@uw.edu

Abstract

The Centers for Disease Control and Prevention (CDC) Sexually Transmitted Disease (STD) Treatment Guidelines were last updated in 2006. To update the “Clinical Guide to Prevention Services” section of the 2010 CDC STD Treatment Guidelines, we reviewed the recent science with reference to interventions designed to prevent acquisition of STDs, including human immunodeficiency virus (HIV) infection. Major interval developments include (1) licensure and uptake of immunization against genital human papillomavirus, (2) validation of male circumcision as a potent prevention tool against acquisition of HIV and some other sexually transmitted infections (STIs), (3) failure of a promising HIV vaccine candidate to afford protection against HIV acquisition, (4) encouragement about the use of antiretroviral agents as preexposure prophylaxis to reduce risk of HIV and herpes simplex virus acquisition, (5) enhanced emphasis on expedited partner management and rescreening for persons infected with Chlamydia trachomatis and Neisseria gonorrhoeae, (6) recognition that behavioral interventions will be needed to address a new trend of sexually transmitted hepatitis C among men who have sex with men, and (7) the availability of a modified female condom. A range of preventive interventions is needed to reduce the risks of acquiring STI, including HIV infection, among sexually active people, and a flexible approach targeted to specific populations should integrate combinations of biomedical, behavioral, and structural interventions. These would ideally involve an array of prevention contexts, including (1) communications and practices among sexual partners, (2) transactions between individual clients and their healthcare providers, and (3) comprehensive population-level strategies for prioritizing prevention research, ensuring accurate outcome assessment, and formulating health policy.

PDF

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3213401/pdf/cir695.pdf

August 7, 2013 at 2:31 pm

Immunotherapy of human papilloma virus induced disease.

Open Virol J. 2012;6:257-63.

van der Burg SH.

Source

Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands.

Abstract

Immunotherapy is the generic name for treatment modalities aiming to reinforce the immune system against diseases in which the immune system plays a role. The design of an optimal immunotherapeutic treatment against chronic viruses and associated diseases requires a detailed understanding of the interactions between the target virus and its host, in order to define the specific strategies that may have the best chance to deliver success at each stage of disease. Recently, a first series of successes was reported for the immunotherapy of Human Papilloma Virus (HPV)-induced premalignant diseases but there is definitely room for improvement. Here I discuss a number of topics that in my opinion require more study as the answers to these questions allows us to better understand the underlying mechanisms of disease and as such to tailor treatment.

PDF

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3547504/pdf/TOVJ-6-257.pdf

May 2, 2013 at 9:05 pm

Sexually Transmitted Diseases (STDs) – Questions & Answers – 2010 Treatment Guidelines

The questions contained on this webpage were submitted by participants during the “2010 STD Treatment Guidelines Webinar: An Overview by CDC and the NNPTC” which aired on January 13, 2011.

The answers were composed by STD clinical experts in the National Network of STD/HIV Prevention Training Centers (NNPTC) and the CDC, edited by the webinar panel members (Gail Bolan, MD; Edward (Ned) Hook III, MD; and Jeanne Marrazzo, MD, MPH) and then reviewed and edited by Kimberly Workowski, MD, the lead author of the 2010 STD Treatment Guidelines, to ensure that the answers were aligned with the current STD Treatment Guidelines.

This webinar is the first in a series of STD Treatment Guidelines webinars produced by the CDC and the NNPTC following the release of the 2010 Treatment Guidelines in December, 2010.

More than 150 questions were submitted following a webinar on the 2010 STD Treatment Guidelines. The questions and their answers are now available, including answers on the following topics.

Click on a category below to view questions and answers:

Children and Adolescents

Chlamydia

Chlamydia/Gonorrhea Retesting

Expedited Partner Therapy

Genital Herpes

Gonorrhea

Human Papillomavirus (HPV)

Lymphogranuloma Venereum (LGV)

Miscellaneous

Mycoplasma genitalium

Pelvic Inflammatory Disease (PID)

Sexual Assault

STD Screening

Syphilis

Vaginitis

FULL TEXT

http://www.cdc.gov/std/treatment/2010/QandA/default.htm?s_CID=govd-std-009

March 9, 2013 at 11:57 am

Treatment failure of pharyngeal gonorrhoea with internationally recommended first-line ceftriaxone verified in Slovenia, September 2011.

Euro Surveill. 2012 Jun 21;17(25).

Unemo M, Golparian D, Potočnik M, Jeverica S.

Source

World Health Organization Collaborating Centre for Gonorrhoea and other Sexually Transmitted Infections, Swedish Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Microbiology, Örebro University Hospital, Örebro, Sweden. magnus.unemo@orebroll.se

Abstract

We describe the second case in Europe of verified treatment failure of pharyngeal gonorrhoea, caused by an internationally occurring multidrug-resistant gonococcal clone, with recommended first-line ceftriaxone 250 mg in Slovenia. This is of grave concern since ceftriaxone is last remaining option for empirical treatment. Increased awareness of ceftriaxone failures, more frequent test-of-cure, strict adherence to regularly updated treatment guidelines, and thorough verification/falsification of suspected treatment failures are essential globally. New effective treatment options are imperative.

PDF

http://www.eurosurveillance.org/images/dynamic/EE/V17N25/art20200.pdf

February 28, 2013 at 2:43 pm

The 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults recommends dual antimicrobial therapy.

Euro Surveill. 2012 Nov 22;17(47).

Unemo M; European STI Guidelines Editorial Board.

PDF

http://www.eurosurveillance.org/images/dynamic/EE/V17N47/art20323.pdf

 

February 28, 2013 at 2:41 pm

Tackling multidrug-resistant gonorrhea: how should we prepare for the untreatable?

Expert Rev Anti Infect Ther. 2012 Aug;10(8):831-3.

Kidd S, Kirkcaldy R, Weinstock H, Bolan G.

PDF

http://www.expert-reviews.com/doi/pdfplus/10.1586/eri.12.69

February 28, 2013 at 2:40 pm

Update to CDC’s Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections.

MMWR Morb Mortal Wkly Rep. 2012 Aug 10;61(31):590-4.

Centers for Disease Control and Prevention (CDC).

Abstract

Gonorrhea is a major cause of serious reproductive complications in women and can facilitate human immunodeficiency virus (HIV) transmission. Effective treatment is a cornerstone of U.S. gonorrhea control efforts, but treatment of gonorrhea has been complicated by the ability of Neisseria gonorrhoeae to develop antimicrobial resistance. This report, using data from CDC’s Gonococcal Isolate Surveillance Project (GISP), describes laboratory evidence of declining cefixime susceptibility among urethral N. gonorrhoeae isolates collected in the United States during 2006-2011 and updates CDC’s current recommendations for treatment of gonorrhea. Based on GISP data, CDC recommends combination therapy with ceftriaxone 250 mg intramuscularly and either azithromycin 1 g orally as a single dose or doxycycline 100 mg orally twice daily for 7 days as the most reliably effective treatment for uncomplicated gonorrhea. CDC no longer recommends cefixime at any dose as a first-line regimen for treatment of gonococcal infections. If cefixime is used as an alternative agent, then the patient should return in 1 week for a test-of-cure at the site of infection.

FULL TEXT

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6131a3.htm

PDF (see pag. 590)

http://www.cdc.gov/mmwr/pdf/wk/mm6131.pdf

February 28, 2013 at 2:39 pm

Older Posts Newer Posts


Calendar

April 2014
M T W T F S S
« Mar    
 123456
78910111213
14151617181920
21222324252627
282930  

Posts by Month

Posts by Category


Follow

Get every new post delivered to your Inbox.

Join 70 other followers